Rafael Holdings, Inc. (RFL)

NYQ – Real vaqt narxi. Valyuta: USD

2.76

+0.05 (1.85%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

2.79

+0.03 (1.09%)

Bozordan keyin: Jun 26, 2026, 7:48 PM EDT

11.06.2026

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

10.06.2026

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC).

22.04.2026

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease

16.03.2026

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.

11.12.2025

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025.

29.10.2025

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks

28.10.2025

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director.

Videolar

No Data

There is no data to display

Press-relizlar

11.06.2026

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

10.06.2026

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

22.04.2026

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

16.03.2026

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.

Rafael Holdings, Inc. (RFL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rafael Holdings, Inc. (RFL)

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Videolar

No Data

Press-relizlar

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Videolar

No Data

Press-relizlar

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Search stocks

Rafael Holdings, Inc. (RFL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rafael Holdings, Inc. (RFL)

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Videolar

No Data

Press-relizlar

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Videolar

No Data

Press-relizlar

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results